Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Pharmacotherapy of pervasive developmental disorders  

This is a mentored Research Career Development Award to support the career development of clinical investigators in patient-oriented research. Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS) is a highly prevalent disorder often associated with severe irritability that impedes participation in educational, therapeutic, and vocational programs, with escalating costs of care. Thus, the development of safe and effective pharmacotherapies that improve irritability is clearly relevant to public health. The investigator will conduct a double-blind, placebo-controlled and open-label continuation study of aripiprazole for irritability in 60 children and adolescents with PDD-NOS. Project Status


Funder National Institutes of Health
Fiscal Year Funding $184,259.00
Project Number 5K23MH082119-02
Principal Investigator Stigler, Kimberly
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4LC. Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015. IACC Recommended Budget: $10,000,000 over 5 years.
Federal or Private? Federal
Institution Indiana University-Purdue University Indianapolis
State/Country Indiana
Web Link 1 Pharmacotherapy of pervasive developmental disorders (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
History/Related Projects Pharmacotherapy of pervasive developmental disorders | $184,587.00 | 2010 | 5K23MH082119-03
Pharmacotherapy of pervasive developmental disorders | $184,202.00 | 2008 | K23MH082119-01A1